Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
03 5월 2024 - 5:05AM
Business Wire
Conference Call Scheduled for Thursday, May 9,
2024 at 4:30 p.m. ET.
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that
the company will release first quarter 2024 financial results on
Thursday, May 9, 2024, after the close of market. Revance will host
a corresponding conference call and a live webcast at 1:30 p.m. PT
/ 4:30 p.m. ET on the same day to discuss the results and provide a
corporate update.
Individuals interested in listening to the conference call may
do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599
for other locations and reference conference ID 663066, or from the
webcast link in the investor relations section of the company's
website at www.revance.com.
A webcast replay will be available beginning May 9, 2024, at
4.30 p.m. PT / 7.30 p.m. ET to August 9, 2024, at 4.30 p.m. PT /
7.30 p.m. ET. To access the replay, please register via the webcast
link on the events page. The webcast will be available in the
investor relations section on the company's website for 90 days
following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
enhance patient outcomes and physician experiences. Revance’s
portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for
injection and the RHA® Collection of dermal fillers in the U.S.
Revance has also partnered with Viatris Inc. to develop a
biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun
Pharmaceutical to commercialize DAXXIFY® in China.
Revance’s global headquarters and experience center is located
in Nashville, Tennessee. Learn more at Revance.com,
RevanceAesthetics.com, DAXXIFY.com,
HCP.DAXXIFYCervicalDystonia.com, or connect with us on
LinkedIn.
“Revance”, the Revance logo, and DAXXIFY are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA are trademarks of TEOXANE SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502428487/en/
Investors Laurence Watts, 619-916-7620
laurence@newstreetir.com
Media Revance@evolvemkd.com
Revance Therapeutics (NASDAQ:RVNC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Revance Therapeutics (NASDAQ:RVNC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
